Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31

PURPOSE: Recent trials have shown potential benefit of extended adjuvant endocrine therapy and relatively high risk of recurrence (RoR) after 5 years in hormone receptor-positive (HR+) human epidermal growth factor receptor 2–negative (HER2−) breast cancer. Although risk of late relapse in HR+ HER2−...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Chumsri, Saranya, Li, Zhuo, Serie, Daniel J., Mashadi-Hossein, Afshin, Colon-Otero, Gerardo, Song, Nan, Pogue-Geile, Katherine L., Gavin, Patrick G., Paik, Soonmyung, Moreno-Aspitia, Alvaro, Perez, Edith A., Thompson, E. Aubrey
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6900835/
https://ncbi.nlm.nih.gov/pubmed/31622131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00443
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars